NYSE:MED - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2025	655	17	34	42	2
12/31/2024	660	9	30	35	2
3/31/2024	898	68	85	91	N/A
12/31/2023	1,072	99	141	148	N/A
9/30/2023	1,218	120	174	189	N/A
6/30/2023	1,373	133	200	214	N/A
3/31/2023	1,530	142	199	215	N/A
12/31/2022	1,599	144	178	195	N/A
9/30/2022	1,639	151	116	135	N/A
6/30/2022	1,662	157	68	96	N/A
3/31/2022	1,603	165	40	73	N/A
12/31/2021	1,526	164	60	95	N/A
9/30/2021	1,413	158	97	122	N/A
6/30/2021	1,271	150	130	147	N/A
3/31/2021	1,097	125	174	184	N/A
12/31/2020	935	103	139	145	N/A
9/30/2020	841	95	140	145	N/A
6/30/2020	759	76	118	121	N/A
3/31/2020	726	76	72	78	N/A
12/31/2019	714	78	74	84	N/A
9/30/2019	689	74	70	80	N/A
6/30/2019	638	72	60	69	N/A
3/31/2019	568	64	67	76	N/A
12/31/2018	501	56	56	61	N/A
9/30/2018	433	47	51	55	N/A
6/30/2018	371	40	57	61	N/A
3/31/2018	330	34	51	55	N/A
12/31/2017	302	28	N/A	43	N/A
9/30/2017	286	25	N/A	33	N/A
6/30/2017	277	24	N/A	27	N/A
3/31/2017	273	20	N/A	24	N/A
12/31/2016	275	18	N/A	25	N/A
9/30/2016	273	18	N/A	28	N/A
6/30/2016	271	17	N/A	30	N/A
3/31/2016	272	19	N/A	27	N/A
12/31/2015	273	20	N/A	29	N/A
9/30/2015	274	18	N/A	28	N/A
6/30/2015	277	18	N/A	27	N/A
3/31/2015	279	19	N/A	25	N/A
12/31/2014	285	21	N/A	26	N/A
9/30/2014	267	27	N/A	33	N/A
6/30/2014	285	27	N/A	31	N/A
3/31/2014	307	28	N/A	38	N/A
12/31/2013	324	27	N/A	42	N/A
9/30/2013	363	21	N/A	35	N/A
6/30/2013	367	22	N/A	37	N/A

アナリストによる今後の成長予測

収入対貯蓄率: MEDの収益は今後 3 年間で減少すると予測されています (年間-85.8% )。

収益対市場: MEDの収益は今後 3 年間で減少すると予測されています (年間-85.8% )。

高成長収益: MEDの収益は今後 3 年間で減少すると予測されています。

収益対市場: MEDの収益は今後 3 年間で減少すると予想されています (年間-17.8% )。

高い収益成長: MEDの収益は今後 3 年間で減少すると予測されています (年間-17.8% )。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: MEDの自己資本利益率が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です

Medifast 将来の成長

Future 基準チェック /06

主要情報

今後の成長に関する最新情報

Price target decreased by 15% to US$21.25

Consensus EPS estimates fall by 54%

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Consensus revenue estimates fall by 15%

Medifast Provides Earnings Guidance for the First Quarter of 2024

Price target decreased by 14% to US$62.50

Recent updates

Investor sentiment deteriorates as stock falls 16%

Price target decreased by 15% to US$21.25

Medifast: Significant Undervaluation Even As Struggles Persist

At US$22.76, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Lacklustre Performance Is Driving Medifast, Inc.'s (NYSE:MED) 32% Price Drop

Medifast's (NYSE:MED) Conservative Accounting Might Explain Soft Earnings

Investor sentiment deteriorates as stock falls 25%

Consensus EPS estimates fall by 54%

The Returns On Capital At Medifast (NYSE:MED) Don't Inspire Confidence

First quarter 2024 earnings: EPS misses analyst expectations

Medifast, Inc. Provides Earnings Guidance for the Second Quarter of 2024

Medifast, Inc. to Report Q1, 2024 Results on Apr 29, 2024

Medifast: Cheap Valuation, Uncertain Future

Independent Director recently sold US$109k worth of stock

Independent Director notifies of intention to sell stock

Medifast Is Getting Attractive

Investor sentiment deteriorates as stock falls 17%

Consensus revenue estimates fall by 15%

New major risk - Revenue and earnings growth

Medifast, Inc.'s (NYSE:MED) 26% Dip In Price Shows Sentiment Is Matching Earnings

Full year 2023 earnings: EPS misses analyst expectations

Medifast Provides Earnings Guidance for the First Quarter of 2024

Medifast, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Price target decreased by 14% to US$62.50

Medifast Share Price Loses Weight, But Is There Still Value To Be Had?

Investor sentiment deteriorates as stock falls 16%

Are Investors Undervaluing Medifast, Inc. (NYSE:MED) By 47%?

Medifast: Good On Paper, But A Slowdown In Sales Is Very Worrisome

Is It Too Late To Consider Buying Medifast, Inc. (NYSE:MED)?

Consensus EPS estimates increase by 11%, revenue downgraded

Medifast: Unveiling A Challenge Beyond Weight Loss Drugs

Now 21% undervalued after recent price drop

Medifast, Inc. Provides Earnings Guidance for the Full Year 2023

New minor risk - Insider selling

Medifast, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Medifast: The Race To Weight-Loss Drugs Not Lost Yet

Medifast, Inc. Announces Optavia Active Now Available

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on November 7, 2023

Lead Independent Director notifies of intention to sell stock

Price target decreased by 14% to US$80.00

Medifast, Inc. Provides Earnings Guidance for the Third Quarter 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Medifast: Take Advantage Of Pessimism Over Weight Loss Drugs

Price target increased by 31% to US$93.00

Medifast Unveils New Product Line, Optavia Active

Is Now An Opportune Moment To Examine Medifast, Inc. (NYSE:MED)?

Medifast, Inc. to Report Q2, 2023 Results on Aug 07, 2023

In The Murky MLM Space, Medifast Might Actually Hold Some Promise

Now 20% undervalued after recent price drop

Estimating The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Medifast, Inc. Declares Quarterly Cash Dividend, Payable on August 8, 2023

Medifast: In Survival Mode Against Diet Pills And The Recession

Medifast Holds Value During Headwinds

Medifast, Inc., Annual General Meeting, Jun 14, 2023

Consensus EPS estimates fall by 25%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Independent Director notifies of intention to sell stock

Consensus revenue estimates fall by 22%

Full year 2022 earnings: EPS exceeds analyst expectations

Medifast Non-GAAP EPS of $3.70 beats by $1.48, revenue of $337.2M beats by $7.1M

Medifast, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Medifast: A Low Earnings Multiple Despite Strong Financial Performance

At US$117, Is Medifast, Inc. (NYSE:MED) Worth Looking At Closely?

Medifast, Inc. Announces Quarterly Dividend, Payable on February 7, 2023

Medifast declares $1.64 dividend

A Look At The Intrinsic Value Of Medifast, Inc. (NYSE:MED)

Price target decreased to US$106

Insufficient new directors

Medifast's (NYSE:MED) Sluggish Earnings Might Be Just The Beginning Of Its Problems